Canopy Growth (CGC) Total Current Liabilities (2017 - 2026)
Canopy Growth (CGC) reported Total Current Liabilities of $115.5 million for Q1 2026, up 60.88% on a YoY basis from $71.8 million in Q1 2025, and up 47.37% sequentially from $78.4 million in Q4 2025.
Canopy Growth (CGC) Total Current Liabilities (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Total Current Liabilities data on file, last reported at $115.5 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 60.88% year-over-year to $115.5 million; the trailing twelve-month figure through Mar 2026 stood at $115.5 million (up 60.88% YoY), and the FY2026 full-year result was $115.5 million, up 60.88% from the prior year.
- Total Current Liabilities rose to $115.5 million in Q1 2026, from $78.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $594.6 million in Q1 2023 to a low of $70.1 million in Q3 2025.
- A 5-year average of $226.1 million and a median of $169.6 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities jumped 253.28% in 2023 and plunged 71.08% in 2025, its largest moves.
- Tracing CGC's Total Current Liabilities over 5 years: stood at $500.3 million in 2022, then plunged by 66.11% to $169.6 million in 2023, then plunged by 44.92% to $93.4 million in 2024, then decreased by 16.07% to $78.4 million in 2025, then surged by 47.37% to $115.5 million in 2026.
- Business Quant data shows CGC's Total Current Liabilities at $115.5 million in Q1 2026, $78.4 million in Q4 2025, and $70.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | 115.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 115.54 Mn |
| Dec 31, 2025 | 78.40 Mn |
| Sep 30, 2025 | 70.07 Mn |
| Jun 30, 2025 | 79.86 Mn |
| Mar 31, 2025 | 71.82 Mn |
| Dec 31, 2024 | 93.41 Mn |
| Sep 30, 2024 | 239.44 Mn |
| Jun 30, 2024 | 169.92 Mn |
| Mar 31, 2024 | 248.35 Mn |
| Dec 31, 2023 | 169.58 Mn |
| Sep 30, 2023 | 161.80 Mn |
| Jun 30, 2023 | 335.86 Mn |
| Mar 31, 2023 | 594.60 Mn |
| Dec 31, 2022 | 500.33 Mn |
| Sep 30, 2022 | 428.33 Mn |
| Jun 30, 2022 | 317.33 Mn |
| Mar 31, 2022 | 168.31 Mn |
| Dec 31, 2021 | 189.80 Mn |
| Sep 30, 2021 | 206.47 Mn |
| Jun 30, 2021 | 208.37 Mn |